Literature DB >> 25821053

Clinical profile, natural history, and predictors of mortality in patients with acute-on-chronic liver failure (ACLF).

Ivana Mikolasevic1, Sandra Milic, Mladen Radic, Lidija Orlic, Zeljka Bagic, Davor Stimac.   

Abstract

BACKGROUND: Acute-on-chronic liver failure (ACLF) is an increasingly recognized entity encompassing an acute deterioration of liver function in patients with cirrhosis, either secondary to superimposed liver injury or due to extrahepatic precipitating factors such as infection culminating in the end-organ dysfunction. Its main features are reversibility and high short-term mortality due to multiorgan failure (MOF). We aimed to analyze the clinical, laboratory, and etiological predictors of mortality and outcome in patients with ACLF.
METHODS: We evaluated 1215 patients with chronic liver disease; 90 patients met the criteria for ACLF.
RESULTS: The most common cause of underlying chronic liver disease was alcohol, and the most common acute insult (AI) in those patients was superadded alcoholic hepatitis. In all, 50% of all patients died within 30 days (71.1 % within the first 14 days after admission). MOF was the cause of death in 70 % of cases. On multivariate analysis, high serum potassium, serum creatinine higher than 90 µmol/L, and C-reactive protein > 30 mg/L were found to be independent baseline predictors of mortality. APACHE II (Acute Physiology and Chronic Health Evaluation II) score was the best predictor of short-term mortality (area under the curve (AUC), 0.878). MOF was a valuable predictor of mortality (AUC, 0.923); 33 of 35 patients who had MOF at admission died. Presence of positive systemic inflammatory response syndrome criteria at admission was also correlated with in-hospital mortality (AUC, 0.742).
CONCLUSION: ACLF is a serious condition with high short-term mortality. Because ACLF is reversible, it is necessary to identify at-risk patients as soon as possible to treat acute events in a timely manner.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25821053     DOI: 10.1007/s00508-015-0707-9

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  26 in total

Review 1.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

2.  Prediction of the prognosis in patients with acute-on-chronic hepatitis using the MELD scoring system.

Authors:  Jian-Wu Yu; Gui-Qiang Wang; Shu-Chen Li
Journal:  J Gastroenterol Hepatol       Date:  2006-10       Impact factor: 4.029

3.  Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.

Authors:  Guadalupe Garcia-Tsao; Arun J Sanyal; Norman D Grace; William Carey
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

4.  Defining acute-on-chronic liver failure: will East and West ever meet?

Authors:  Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2013-04-24       Impact factor: 22.682

5.  Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Kun Huang; Jin-Hua Hu; Hui-Fen Wang; Wei-Ping He; Jing Chen; Xue-Zhang Duan; Ai-Min Zhang; Xiao-Yan Liu
Journal:  World J Gastroenterol       Date:  2011-08-07       Impact factor: 5.742

Review 6.  Acute-on chronic liver failure.

Authors:  Rajiv Jalan; Pere Gines; Jody C Olson; Rajeshwar P Mookerjee; Richard Moreau; Guadalupe Garcia-Tsao; Vicente Arroyo; Patrick S Kamath
Journal:  J Hepatol       Date:  2012-06-28       Impact factor: 25.083

7.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

Review 8.  [Acute-on-chronic liver failure (ACLF)--a new entity in hepatology?].

Authors:  Ivana Mikolasević; Mladen Radić; Sandra Milić; Davor Stimac
Journal:  Lijec Vjesn       Date:  2013 Nov-Dec

Review 9.  Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation.

Authors:  Len Verbeke; Frederik Nevens; Wim Laleman
Journal:  Crit Care       Date:  2011-10-25       Impact factor: 9.097

10.  Liver transplantation for acute-on-chronic liver failure.

Authors:  Albert C Chan; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; See Ching Chan; Kelvin K Ng; Boon Hun Yong; Alexander Chiu; Banny K Lam
Journal:  Hepatol Int       Date:  2009-08-13       Impact factor: 6.047

View more
  4 in total

Review 1.  Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

Authors:  Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

2.  Patient Frailty Is Independently Associated With the Risk of Hospitalization for Acute-on-Chronic Liver Failure.

Authors:  Shivani Shah; David S Goldberg; David E Kaplan; Vinay Sundaram; Tamar H Taddei; Nadim Mahmud
Journal:  Liver Transpl       Date:  2020-10-28       Impact factor: 5.799

3.  Acute on Chronic Liver Failure-In-Hospital Predictors of Mortality in ICU.

Authors:  Sujay Kulkarni; Mithun Sharma; Padaki N Rao; Rajesh Gupta; Duvvuru N Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-11-23

4.  Value of Liver Regeneration in Predicting Short-Term Prognosis for Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure.

Authors:  Xiaoping Wang; Mengying Sun; Xianjun Yang; Liucun Gao; Min Weng; Dehui Yang; Hongyong Li; Xiaolei Zhou; Jiani Li; Sen Qin; Dejiang Zhou; Xiaoling Wu; Shanhong Tang; Weizheng Zeng
Journal:  Biomed Res Int       Date:  2020-08-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.